Fig. 2: Transcriptomic analysis highlighting the upregulation of MCM2 and MCM5 in Niraparib-resistant ovarian cancer cell lines.

A Volcano plot of the differentially expressed genes in control and niraparib-treated A2780 cells. Red dots represent up-regulated genes and green dots represent down-regulated genes. B KEGG pathway enrichment of differentially expressed genes between control and niraparib-treated A2780 cells. C Volcano plot of the differentially expressed genes in niraparib-treated A2780 and A2780R cells. Red dots represent up-regulated genes and green dots represent down-regulated genes. D KEGG pathway enrichment of differentially expressed genes between niraparib-treated A2780 and A2780R cells. E Real-time PCR assays to determine mRNA expression levels of MCMs and MCMBP in A2780 cells after 48 h of niraparib treatment. F Real-time PCR assays to determine mRNA expression levels of MCMs and MCMBP in SKOV3 cells after 48 h of niraparib treatment. G Western blots of A2780 and SKOV3 cells of MCM2-7 under niraparib treatment. H The mRNA expressions of MCM2, MCM5, CDK4, and CDK6 were examined by real-time PCR assays between parental and niraparib-resistant cells. I The protein expressions of MCM2 and MCM5 were examined by western blot assays between parental and niraparib-resistant cells. J Co-IP assay revealing the altered MCM2–MCM5 interaction in A2780, A2780R, SKOV3, and SKOV3R cells following niraparib treatment versus control. K The expressions of MCM2, MCM5, RB, P-RB, RAD51, E2F1, and γH2AX were examined by western blot assays between A2780, A2780R, SKOV3 and SKOV3R. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.